News & Media

Life sciences industry expected to hit $1.5-T milestone by 2022

Health care digitization and consumerization, a tsunami of patient data and the emergence of value-based reimbursement models are shaking things up in this ever-evolving industry. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics is driving regulatory and commercial changes that make this a very exciting time, according to Frost & Sullivan’s recent analysis, Global Life Sciences Industry Outlook, 2018.